Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BT Pharma appoints Thierry Hercend president of supervisory board

This article was originally published in Scrip

Executive Summary

BT Pharma, a French biopharmaceutical company developing innovative immunotherapies to treat diseases and cancer caused by the human papillomavirus, has appointed Professor Thierry Hercend president of its supervisory board. Professor Hercend has more than 30 years' academic and pharmaceutical experience in various therapeutic areas, including oncology and inflammatory diseases. From 2002-05, he was vice-president of oncology research of Aventis. He has also worked at Vertex Pharmaceuticals, LFB (Laboratoire Français du Fractionnement et des Biotechnologies) and Roussel Uclaf.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts